Pharm-Olam Italy

Pharm-Olam has conducted clinical trials in Italy since 2001 and we have an office in Milan. Milan has the most clinical trials of any city in Italy with 45.2% of all studies having at least one site in Milan in 2012. Our studies in Italy have supported successful US NDA and EMA approval in hepatitis.

More information on the types of studies and clinical trial metrics can be found in Italy's Agenzia Italiana del Farmaco 2012 report.

Pharm-Olam offers comprehensive services and functional outsourcing for Phase I to IV clinical research studies in Italy, including monitoring, regulatory, pharmacovigilance (including EudraVigilance), data management, project management, and biostatistics.

For more information on conducting clinical trials with Pharm-Olam in Italy, please Contact Us.

Office Location: Milan

Italy Demographics

Population: 61.2 million (73% urbanized), with over 2 million in Milan
Median Age: 43.3 years
Language: Italian
Market: In 2010 Italy was the world's 6th largest pharmaceutical market, and has a well established pharmaceutical manufacturing industry.

Regulatory Authorities

Italian Medicines Agency (in English)
Ministry of Health (in Italian)
Istituto Superiore di Sanità (ISS)

Clinical Trials in Italy

clinicaltrials.gov Active Studies
EU Clinical Trials Register Active Studies

Argentina (Buenos Aires), Belarus (Minsk), Belgium (Brussels), Brazil (São Paulo), Bulgaria (Sofia), Canada (Toronto), Croatia (Zagreb), Czech Rep. (Prague), Georgia (Tbilisi), Germany (Munich), Hungary (Budapest), India (Bangalore), Italy (Milan), Kazakhstan (Almaty), Mexico (Mexico City), Poland (Warsaw), Romania (Bucharest), Russia (Moscow, St. Petersburg, Novosibirsk), Serbia (Belgrade), Spain (Madrid), South Africa (Johannesburg), Ukraine (Kiev), United Kingdom (London), United States (Houston, Princeton, Research Triangle Park)